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Big pharma under the spotlight
In February 2013, in what the British Medical Journal 
called a ‘spectacular public relations coup’, Andrew 
Witty, the chief executive officer of GlaxoSmithKline 
(GSK), announced that the company would sign up 
to AllTrials – a campaign that has been pressing drug 
companies to disclose all detailed clinical study reports and drug trial 
results, not just those with favourable results.[1] 
The story behind this announcement goes back a long way. 
GSK itself was fined $3 billion in 2012 in the USA for selling the 
antidepressant drug paroxetine for unapproved use in children, for 
concealing safety evidence on the company’s leading diabetes product 
from the Food and Drug Administration, and for offering doctors 
lavish incentives to prescribe its medicines.[2]
In 2009 the BMJ started its first ‘open data campaign’. The 
drug under the spotlight was Tamiflu, produced by Roche and 
recommended for the treatment of influenza. In that year, Roche 
made a public promise to release full trial reports for Tamiflu, in 
response to an investigation by the BMJ and Cochrane collaborators 
Peter Doshi and Tom Jefferson.[3-6] In September 2009 Jefferson 
asked Roche for the unpublished data set that Roche used in an 
analysis published in 2003, for use the following month to update 
the Cochrane Collaboration’s review on neuraminidase inhibitors 
in healthy adults. After asking Jefferson to sign a confidentiality 
agreement promising that he would not publish the data in full, 
Roche declined to supply the data set because they had also been 
approached by another group doing a similar meta-analysis and 
didn’t want conflict. According to Roche, their study reports had also 
been shared with the regulatory authorities.
Jefferson never received the study reports, and the Cochrane 
review published 2 months later in the BMJ[6] said that because 8 of 
the 10 randomised controlled trials on which effectiveness claims 
were based were never published, the evidence could not be relied on. 
The 2 published studies were funded by Roche and authored by Roche 
employees and external experts paid by Roche. Roche promised to 
make full study reports on the 10 trials available.[3] To date, this has 
never happened. In the meantime several organisations, including 
the World Health Organization, the National Health Service in the 
UK, the Centers for Disease Control in the USA and the European 
Medicines Agency, have encouraged the use and stockpiling of 
Tamiflu – all without seeing the full study and trial reports.
Tamiflu was the final insult that instituted the open data campaign. 
But it was not the first example. Looking back through the literature, 
there are myriad reports of drugs that have come to market on the 
back of trials that have never been seen in full by regulators. Rofecoxib 
(Merck) was introduced in 1999 as an effective, safer alternative to 
non-steroidal anti-inflammatory drugs for treating pain associated 
with osteo-arthritis. It was subsequently withdrawn in September 
2004 after being found to increase the risk of cardiovascular disease, 
and Merck faces claims from nearly 30  000 people who had 
cardiovascular events while taking the drug.[7] In November 2004 
The Lancet published a meta-analysis of the available safety studies 
of rofecoxib.[8] In this, the authors concluded that, because of its 
cardiovascular risk, rofecoxib should have been withdrawn several 
years earlier.
The list goes on – rosiglitazone, approved in 2000 for diabetes 
treatment, was withdrawn by the European Medicines Agency in 2010 
because of increased rates of myocardial infarction in some patients 
receiving the drug. The UK’s Medicines and Healthcare Products 
Regulatory Agency concurred, saying that the risks associated with 
the drug outweigh the benefits – but it has yet to release the clinical 
trial data to explain its decision.
In his controversial book Bad Pharma, Ben Goldacre[9] says 
that ‘drugs are tested by the people who manufacture them, in 
poorly designed trials, on hopelessly small numbers of weird, 
unrepresentative patients, and analysed using techniques which are 
flawed by design, in such a way that they exaggerate the benefits of 
treatments’. If this sounds extreme, take a look at Minerva, published 
recently in the BMJ – ‘Diabetologia reports this week [17 April 
2013] that the majority of current trials in diabetes registered on 
ClinicalTrials.gov exclude older people, are of short duration, involve 
drug therapy rather than preventive or non-drug interventions and 
do not focus on important cardiovascular outcomes’.[10]
The BMJ made the decision that, 
as of January this year, it will no 
longer publish any trial of drugs 
or devices where the authors do 
not commit to making the relevant 
anonymised patient level data 
available, upon reasonable request. 
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